These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24824346)

  • 1. Potency of an inactivated influenza vaccine prepared from A/duck/Hong Kong/960/1980 (H6N2) against a challenge with A/duck/Vietnam/OIE-0033/2012 (H6N2) in mice.
    Nishi T; Sakoda Y; Okamatsu M; Kida H
    Arch Virol; 2014 Oct; 159(10):2567-74. PubMed ID: 24824346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency of an inactivated influenza vaccine prepared from A/duck/Mongolia/119/2008 (H7N9) against the challenge with A/Anhui/1/2013 (H7N9).
    Chu DH; Sakoda Y; Nishi T; Hiono T; Shichinohe S; Okamatsu M; Kida H
    Vaccine; 2014 Jun; 32(28):3473-9. PubMed ID: 24793949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potency of an inactivated influenza vaccine prepared from A/duck/Hokkaido/162/2013 (H2N1) against a challenge with A/swine/Missouri/2124514/2006 (H2N3) in mice.
    Suzuki M; Okamatsu M; Hiono T; Matsuno K; Sakoda Y
    J Vet Med Sci; 2017 Nov; 79(11):1815-1821. PubMed ID: 28993601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An H9N2 influenza virus vaccine prepared from a non-pathogenic isolate from a migratory duck confers protective immunity in mice against challenge with an H9N2 virus isolated from a girl in Hong Kong.
    Nomura N; Sakoda Y; Soda K; Okamatsu M; Kida H
    J Vet Med Sci; 2012 Apr; 74(4):441-7. PubMed ID: 22123308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of antibody induction and protection against influenza virus infection by DNA immunization with HA, HAe, and HA1 in mice.
    Chen J; Liu Q; Chen Q; Xiong C; Yao Y; Wang H; Wang H; Chen Z
    Arch Virol; 2014 Apr; 159(4):689-700. PubMed ID: 24132721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
    Johansson BE
    Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
    Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
    Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia.
    Guo YJ; Krauss S; Senne DA; Mo IP; Lo KS; Xiong XP; Norwood M; Shortridge KF; Webster RG; Guan Y
    Virology; 2000 Feb; 267(2):279-88. PubMed ID: 10662623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative immunogenicity of recombinant adenovirus-vectored vaccines expressing different forms of hemagglutinin (HA) proteins from the H5 serotype of influenza A viruses in mice.
    Hu X; Meng W; Dong Z; Pan W; Sun C; Chen L
    Virus Res; 2011 Jan; 155(1):156-62. PubMed ID: 20883733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-exposure treatment with whole inactivated H5N1 avian influenza virus protects against lethal homologous virus infection in mice.
    Hagan M; Ranadheera C; Audet J; Morin J; Leung A; Kobasa D
    Sci Rep; 2016 Jul; 6():29433. PubMed ID: 27405487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic analysis of avian influenza A viruses isolated from domestic waterfowl in live-bird markets of Hanoi, Vietnam, preceding fatal H5N1 human infections in 2004.
    Jadhao SJ; Nguyen DC; Uyeki TM; Shaw M; Maines T; Rowe T; Smith C; Huynh LP; Nghiem HK; Nguyen DH; Nguyen HK; Nguyen HH; Hoang LT; Nguyen T; Phuong LS; Klimov A; Tumpey TM; Cox NJ; Donis RO; Matsuoka Y; Katz JM
    Arch Virol; 2009; 154(8):1249-61. PubMed ID: 19578928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.
    Horimoto T; Takada A; Iwatsuki-Horimoto K; Kawaoka Y
    Vaccine; 2004 Jun; 22(17-18):2244-7. PubMed ID: 15149783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
    Wodal W; Falkner FG; Kerschbaum A; Gaiswinkler C; Fritz R; Kiermayr S; Portsmouth D; Savidis-Dacho H; Coulibaly S; Piskernik C; Hohenadl C; Howard MK; Kistner O; Barrett PN; Kreil TR
    Vaccine; 2012 Jun; 30(31):4625-31. PubMed ID: 22580355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a human H9N2 influenza virus isolated in Hong Kong.
    Saito T; Lim W; Suzuki T; Suzuki Y; Kida H; Nishimura SI; Tashiro M
    Vaccine; 2001 Oct; 20(1-2):125-33. PubMed ID: 11567756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
    Qiu M; Fang F; Chen Y; Wang H; Chen Q; Chang H; Wang F; Wang H; Zhang R; Chen Z
    Biochem Biophys Res Commun; 2006 May; 343(4):1124-31. PubMed ID: 16580631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.
    Ermler ME; Kirkpatrick E; Sun W; Hai R; Amanat F; Chromikova V; Palese P; Krammer F
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28356526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.